Beclabuvir
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
Synonyms | BMS-791325 |
CAS Number | 958002-33-0 |
PubChem (CID) | 56934415 |
ChemSpider | 27289076 |
UNII | MYW1X5CO9S |
Chemical and physical data | |
Formula | C36H45N5O5S |
Molar mass | 659.84 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Beclabuvir (BMS-791325) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection currently in clinical trials. Beclabuvir acts as a NS5B inhibitor.[1]
References
- ↑ Tatum, H.; Thuluvath, P. J.; Lawitz, E.; Martorell, C.; DeMicco, M.; Cohen, S.; Rustgi, V.; Ravendhran, N.; Ghalib, R.; Hanson, J.; Zamparo, J.; Zhao, J.; Cooney, E.; Treitel, M.; Hughes, E. (December 2014). "A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1". Journal of Viral Hepatitis: n/a–n/a. doi:10.1111/jvh.12372.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.